ObsEva increases its share capital to create additional treasury shares

On July 19, 2019, ObsEva SA, a clinical-stage biopharmaceutical company listed on Nasdaq and SIX Swiss Exchange, issued 3'064'048 new shares  out of its authorized share capital. The new shares, were subscribed by one of ObsEva's subsidiaries. They will be used in the company's "at-the-market-offering" (ATM program), which allows the company to offer and sell shares from time to time to raise funds in an efficient manner, as well as for the equity plans of the company and its subsidiaries.

Lenz & Staehelin advised ObsEva in this transaction. The team was led by partner Jacques Iffland (Capital Markets) and consisted of associates Ariel Ben Hattar (Capital Markets) and Federico Trabaldo Togna (Corporate and M&A).